Onconetix Amends License Agreement with Labcorp

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Onconetix ( (ONCO) ) has shared an announcement. On December 6, 2025, Proteomedix AG, a subsidiary of Onconetix, Inc., amended its license agreement with Labcorp to conduct a new validation study for Proclarix, a prostate cancer risk identification tool. The amendment stipulates that Labcorp will not pay royalties for using the risk calculator in the study, while Onconetix will compensate Labcorp up to $300,000 based on milestone achievements during the study. Spark’s Take on ONCO Stock According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform. Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score. To see Spark’s full report on ONCO stock, click here. More about Onconetix Onconetix, Inc. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic products for cancer risk assessment. Its subsidiary, Proteomedix AG, is involved in licensing agreements to leverage intellectual property for product development. Average Trading Volume: 114,317 Technical Sentiment Signal: Sell Current Market Cap: $4.35M For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.